Lyra Therapeutics, INC Form 4 insider transactions

Director W. Bradford Smith has disposed of his entire beneficial ownership stake in Lyra Therapeutics, Inc.

Maria Palasis, a Director and Officer at Lyra Therapeutics, reported a transaction involving 2,000 shares of common stock on April 1, 2026.

Jason Cavalier, Principal Financial Officer at Lyra Therapeutics, Inc., reported a transaction involving 667 shares of common stock on April 1, 2026.

Lyra Therapeutics' Chief Financial Officer, Jason Cavalier, sold 769 shares of common stock on January 6, 2026, to cover tax liabilities from RSU vesting.

Lyra Therapeutics President & CEO Maria Palasis sold 1,702 shares of common stock to cover tax obligations related to RSU vesting, as per a pre-arranged 10b5-1 plan.

Perceptive Advisors and related entities reported the sale of Lyra Therapeutics common stock in mid-November 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

Perceptive Advisors and related entities, a 10% owner and director, reported multiple sales of Lyra Therapeutics common stock totaling 70,390 shares in early November 2025.

Lyra Therapeutics' President & CEO, Maria Palasis, filed an amended Form 4 to correct an erroneous report of stock option acquisition, confirming no beneficial ownership of the previously reported performance stock options.

Lyra Therapeutics' President & CEO, Maria Palasis, earned 3,667 performance stock options after achieving a key milestone.

Lyra Therapeutics' President and CEO, Maria Palasis, sold 1,565 shares of common stock on July 10, 2025, at $8.91 per share to cover tax obligations related to RSU vesting.

Lyra Therapeutics' Chief Financial Officer, Jason Cavalier, sold 684 shares of common stock on July 10, 2025, at $8.91 per share to cover tax obligations related to restricted stock unit vesting, as part of a pre-established Rule 10b5-1 trading plan.

Director Nancy Lynn Snyderman reports the acquisition of 32,000 Restricted Stock Units (RSUs) in Lyra Therapeutics, Inc.

Director W. Bradford Smith reports acquisition of 32,000 Restricted Stock Units in Lyra Therapeutics, Inc.

Director C. Ann Merrifield reports the acquisition of 32,000 Restricted Stock Units (RSUs) in Lyra Therapeutics, Inc. on May 14, 2025.

Director James R. Tobin acquired 32,000 Restricted Stock Units (RSUs) in Lyra Therapeutics, Inc. on May 14, 2025, according to a Form 4 filing.

Maria Palasis, President & CEO of Lyra Therapeutics, received 800,000 restricted stock units (RSUs) on January 8, 2025, vesting in three installments.

Jason Cavalier, CFO of Lyra Therapeutics, reports acquiring 420,000 shares of common stock and disposing of 520,000 shares.

Lyra Therapeutics CEO Maria Palasis acquired 183,333 shares through the vesting of a performance stock option.

Harlan Waksal, Executive Chair of Lyra Therapeutics, acquired 128,333 shares of common stock following the achievement of a performance-based milestone.

Lyra Therapeutics' President and CEO, Maria Palasis, was granted 300,000 restricted stock units (RSUs) on October 16, 2024.

Lyra Therapeutics' Chief Financial Officer, Jason Cavalier, received an award of 100,000 restricted stock units (RSUs) on October 16, 2024.

Director Michael Seth Altman acquired 30,000 stock options in Lyra Therapeutics, Inc. on June 13, 2024.

Director Konstantin Poukalov acquired 30,000 stock options in Lyra Therapeutics, Inc. on June 13, 2024.

Director James R. Tobin reports the acquisition of stock options in Lyra Therapeutics, Inc.

Nancy Lynn Snyderman, a director of Lyra Therapeutics, reported the acquisition of stock options.

Director W. Bradford Smith acquired 30,000 stock options in Lyra Therapeutics, Inc. on June 13, 2024.

Director C. Ann Merrifield acquired stock options in Lyra Therapeutics, Inc. on June 13, 2024.

Harlan Waksal, Executive Chair of Lyra Therapeutics, was granted 275,000 restricted stock units (RSUs) on March 18, 2024, which will vest on January 31, 2025.

Lyra Therapeutics' CEO, Maria Palasis, received stock options for 500,000 shares on March 18, 2024, vesting monthly over four years.